The role of PET in first-line treatment of Hodgkin lymphoma Réf :HematoStat.net : 1 (11) : V21 DOI: 10.1016/S2352-3026(20)30357-4

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia Réf :HematoStat.net : 1 (11) : V20 DOI: 10.1056/NEJMoa2031298

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy Réf :HematoStat.net : 1 (11) : V19 DOI: 10.1056/NEJMc2030164

There is no excerpt because this is a protected post.